Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15032637 | 0.89 | LMNA (0.52) | KMT2AMEN1MAPK1MAPTALDH1A1 | |
| SCHEMBL15032500 | 0.88 | SHMT2 (0.60) | KMT2AMEN1MAPK1MAPTALDH1A1 | |
| SCHEMBL15032502 | 0.88 | MAPT (0.51) | KMT2AMEN1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL15032635 | 0.87 | ALDH1A1 (0.53) | KMT2AMEN1MAPK1MAPTALDH1A1 | |
| SCHEMBL15032503 | 0.86 | MEN1 (0.67) | KMT2AMEN1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL15032636 | 0.86 | SHMT2 (0.50) | KMT2AMEN1MAPK1MAPTALDH1A1 | |
| SCHEMBL15032501 | 0.86 | MAPT (0.53) | KMT2AMEN1MAPK1MAPTALDH1A1 | |
| SCHEMBL15032504 | 0.75 | ALDH1A1 (0.56) | KMT2AMAPTALDH1A1GAARAB9A | |
| SCHEMBL14059008 | 0.72 | NPC1 (0.53) | KMT2AMEN1MAPTSMN1; SMN2GAA | |
| SCHEMBL855488 | 0.71 | HSD17B10 (0.48) | KMT2AMEN1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073941-B2 | Compounds and methods for treating tuberculosis infection | ACADEMIA SINICA (TW) | 2015-07-07 | — | — | US | disclosed |
| US-9073941-B2 | Compounds and methods for treating tuberculosis infection | ACADEMIA SINICA (TW) | 2015-07-07 | — | — | US | disclosed |
| US-20130158037-A1 | COMPOUNDS AND METHODS FOR TREATING TUBERCULOSIS INFECTION | ACADEMIA SINICA (TW) | 2013-06-20 | — | — | US | disclosed |
| US-20130158037-A1 | COMPOUNDS AND METHODS FOR TREATING TUBERCULOSIS INFECTION | ACADEMIA SINICA (TW) | 2013-06-20 | — | — | US | disclosed |
| WO-2012006104-A2 | COMPOUNDS AND METHODS FOR TREATING TUBERCULOSIS INFECTION | Academia Sinica, Taiwan (TW) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158037-A1 | COMPOUNDS AND METHODS FOR TREATING TUBERCULOSIS INFECTION | TALDO1, PGD, DLD | KMT2A 2118/4885MEN1 3731/4885MAPK1 2839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.